Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.

Hardalo C, Lodise TP, Bidell M, Flanagan S, De Anda C, Anuskiewicz S, Prokocimer P.

Expert Opin Drug Saf. 2018 Mar 12:1-9. doi: 10.1080/14740338.2018.1446939. [Epub ahead of print]

PMID:
29528251
2.
3.

Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.

Flanagan SD, Minassian SL, Prokocimer P.

Clin Pharmacol Drug Dev. 2018 Jan 10. doi: 10.1002/cpdd.426. [Epub ahead of print]

PMID:
29319932
4.

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.

Flanagan S, Minassian SL, Passarell JA, Fiedler-Kelly J, Prokocimer P.

J Clin Pharmacol. 2017 Oct;57(10):1290-1294. doi: 10.1002/jcph.928. Epub 2017 May 16. No abstract available.

PMID:
28510339
5.

Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.

Sandison T, De Anda C, Fang E, Das AF, Prokocimer P.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02687-16. doi: 10.1128/AAC.02687-16. Print 2017 May.

6.

Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.

Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P.

Clin Infect Dis. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21.

PMID:
28003218
7.

Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.

Fang E, Muñoz KA, Prokocimer P.

Am J Ther. 2017 Mar/Apr;24(2):e227-e233. doi: 10.1097/MJT.0000000000000534.

PMID:
27941424
8.

Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity InfectionsPooled Analysis of Two Phase 3 Trials.

Joseph WS, Culshaw D, Anuskiewicz S, De Anda C, Prokocimer P.

J Am Podiatr Med Assoc. 2017 Jul;107(4):264-271. doi: 10.7547/15-218. Epub 2016 Aug 17.

PMID:
27533787
9.

Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.

Powers JH 3rd, Das AF, De Anda C, Prokocimer P.

Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13.

PMID:
27530088
10.

Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.

Flanagan S, Litwin J, Fang E, Prokocimer P.

Int J Antimicrob Agents. 2016 Jul;48(1):33-40. doi: 10.1016/j.ijantimicag.2015.12.015. Epub 2016 Jun 2.

PMID:
27342387
11.

Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.

Lodise TP, Bidell MR, Flanagan SD, Zasowski EJ, Minassian SL, Prokocimer P.

J Antimicrob Chemother. 2016 Sep;71(9):2553-8. doi: 10.1093/jac/dkw206. Epub 2016 Jun 17.

PMID:
27317442
12.

Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.

Flanagan S, Prokocimer P.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3246-7. doi: 10.1128/AAC.03127-15. Print 2016 May. No abstract available.

13.

Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.

Bradley JS, Flanagan SD, Arrieta AC, Jacobs R, Capparelli E, Prokocimer P.

Pediatr Infect Dis J. 2016 Jun;35(6):628-33. doi: 10.1097/INF.0000000000001096.

PMID:
26910588
14.

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.

Ortiz-Covarrubias A, Fang E, Prokocimer PG, Flanagan SD, Zhu X, Cabré-Márquez JF, Tanaka T, Passarell J, Fiedler-Kelly J, Nannini EC.

Braz J Infect Dis. 2016 Mar-Apr;20(2):184-92. doi: 10.1016/j.bjid.2015.12.007. Epub 2016 Feb 7.

15.

Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Talbot GH, Powers JH, Hoffmann SC; Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams.

Clin Infect Dis. 2016 Mar 1;62(5):603-7. doi: 10.1093/cid/civ927. Epub 2015 Dec 13.

16.

A closer inspection of tedizolid - authors' reply.

Prokocimer P, Corey GR, Das AF, Moran GJ.

Lancet Infect Dis. 2015 Apr;15(4):375. doi: 10.1016/S1473-3099(15)70103-9. No abstract available.

PMID:
25809888
17.

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P.

Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24.

18.

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J, Passarell J, Radovsky A, Prokocimer P.

Antimicrob Agents Chemother. 2015 Jan;59(1):178-85. doi: 10.1128/AAC.03684-14. Epub 2014 Oct 20.

19.

Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.

Lodise TP, Fang E, Minassian SL, Prokocimer PG.

Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22.

20.

Tedizolid population pharmacokinetics, exposure response, and target attainment.

Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P.

Antimicrob Agents Chemother. 2014 Nov;58(11):6462-70. doi: 10.1128/AAC.03423-14. Epub 2014 Aug 18.

Supplemental Content

Loading ...
Support Center